Isopogen is a privately-owned company developing life-changing cellular medicines. Our patented StemSmart™ technology improves the clinical efficacy of mesenchymal stem cells (MSC), offering a powerful competitive advantage against other MSC products.
Our proprietary cellular medicines made using the StemSmart™ technology are in late stage clinical development to treat several auto-immune conditions including Crohn’s Disease – a debilitating gut illness with a global market worth $7.5 billion each year.
Derived from donor bone barrow, mesenchymal stem cells (MSCs) are isolated and grown, before applying the patented StemSmart™ technology to improve the cells’ clinical efficacy. This manufacturing is completed under a Therapeutic Goods Administration (TGA) license in accordance with Good Manufacturing Practice (GMP). The resulting proprietary cellular medicine is a non-invasive, universal treatment (does not require patient tissue matching) that can be frozen until use.
By moderating the patient’s immune system and supporting tissue regeneration, these products can be a life-changing treatment for patients suffering from some of the most debilitating inflammatory and auto-immune conditions.
Already more than 150 patients have been safely treated with products created using the StemSmart™ technology in Clinical Trials and under Special Access Arrangements. These results have been widely published, including an impressive 80% clinical response and 53% clinical remission in life-threatening (refractory) Crohn’s patients (Phase II study), making the StemSmart™-created product the only MSC treatment clinically-proven to treat this condition.
Led by internationally renowned cellular scientist Dr Marian Sturm, in FY20 Isopogen will work to submit its product application for life-threatening Crohn's to Australia's TGA. If successful, this will ensure wider distribution of this life-changing treatment, and will provide a foundation for international licensing opportunities - potentially helping Crohn's sufferers globally.
Coupled with its patented StemSmart™ manufacturing technology that can be licensed to MSC manufacturers globally, Isopogen aims to maximise the benefits of cellular therapies to patients worldwide.